The Insulin-Like Growth Factor-I Receptor Inhibitor Figitumumab (CP-751,871) in Combination With Docetaxel in Patients With Advanced Solid Tumours: Results of a Phase Ib Dose-Escalation, Open-Label Study
British Journal of Cancer - United Kingdom
doi 10.1038/sj.bjc.6605767
Full Text
Open PDFAbstract
Available in full text
Date
July 1, 2010
Authors
Publisher
Springer Science and Business Media LLC